Cargando…

The incidence and management of cutaneous adverse events of the epidermal growth factor receptor inhibitors

Overexpression of the epidermal growth factor receptor (EGFR) is found in many cancers, including those of the head and neck area, non-small-cell lung cancer, and colorectal, cervical, prostate, breast, ovary, stomach, and pancreatic cancer. The EGFR inhibitors are used at present in the treatment o...

Descripción completa

Detalles Bibliográficos
Autores principales: Owczarek, Witold, Słowińska, Monika, Lesiak, Aleksandra, Ciążyńska, Magdalena, Maciąg, Aldona, Paluchowska, Elwira, Marek-Józefowicz, Luiza, Czajkowski, Rafał
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Termedia Publishing House 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5831275/
https://www.ncbi.nlm.nih.gov/pubmed/29507555
http://dx.doi.org/10.5114/ada.2017.71106
_version_ 1783303139798024192
author Owczarek, Witold
Słowińska, Monika
Lesiak, Aleksandra
Ciążyńska, Magdalena
Maciąg, Aldona
Paluchowska, Elwira
Marek-Józefowicz, Luiza
Czajkowski, Rafał
author_facet Owczarek, Witold
Słowińska, Monika
Lesiak, Aleksandra
Ciążyńska, Magdalena
Maciąg, Aldona
Paluchowska, Elwira
Marek-Józefowicz, Luiza
Czajkowski, Rafał
author_sort Owczarek, Witold
collection PubMed
description Overexpression of the epidermal growth factor receptor (EGFR) is found in many cancers, including those of the head and neck area, non-small-cell lung cancer, and colorectal, cervical, prostate, breast, ovary, stomach, and pancreatic cancer. The EGFR inhibitors are used at present in the treatment of such cancers. Skin lesions that develop during and after cancer treatment may be due to specific cytostatics, molecular-targeted drugs, radiation therapy, complementary therapy, or the cancer itself, and hence knowledge is essential to distinguish between them. The mechanism through which skin toxicity arises during treatment with EGFR inhibitors is not well known, but seems to be due to the modification of the RAS/RAF/MEK/ERK signal path associated with its activation, which results in the similarity between the adverse effects of EGFR inhibitors and the treatment of melanoma with BRAF and MEK inhibitors. The most common side effects are pruritus, xerosis, papulopustular rash, hand-foot skin reaction, alopecia and dystrophy of the hair, and paronychia. This work presents options for prevention and suggestions for managing these adverse events, which are of importance in the care of patients undergoing oncological treatment.
format Online
Article
Text
id pubmed-5831275
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Termedia Publishing House
record_format MEDLINE/PubMed
spelling pubmed-58312752018-03-05 The incidence and management of cutaneous adverse events of the epidermal growth factor receptor inhibitors Owczarek, Witold Słowińska, Monika Lesiak, Aleksandra Ciążyńska, Magdalena Maciąg, Aldona Paluchowska, Elwira Marek-Józefowicz, Luiza Czajkowski, Rafał Postepy Dermatol Alergol Review Paper Overexpression of the epidermal growth factor receptor (EGFR) is found in many cancers, including those of the head and neck area, non-small-cell lung cancer, and colorectal, cervical, prostate, breast, ovary, stomach, and pancreatic cancer. The EGFR inhibitors are used at present in the treatment of such cancers. Skin lesions that develop during and after cancer treatment may be due to specific cytostatics, molecular-targeted drugs, radiation therapy, complementary therapy, or the cancer itself, and hence knowledge is essential to distinguish between them. The mechanism through which skin toxicity arises during treatment with EGFR inhibitors is not well known, but seems to be due to the modification of the RAS/RAF/MEK/ERK signal path associated with its activation, which results in the similarity between the adverse effects of EGFR inhibitors and the treatment of melanoma with BRAF and MEK inhibitors. The most common side effects are pruritus, xerosis, papulopustular rash, hand-foot skin reaction, alopecia and dystrophy of the hair, and paronychia. This work presents options for prevention and suggestions for managing these adverse events, which are of importance in the care of patients undergoing oncological treatment. Termedia Publishing House 2017-10-31 2017-10 /pmc/articles/PMC5831275/ /pubmed/29507555 http://dx.doi.org/10.5114/ada.2017.71106 Text en Copyright: © 2017 Termedia Sp. z o. o. http://creativecommons.org/licenses/by-nc-sa/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
spellingShingle Review Paper
Owczarek, Witold
Słowińska, Monika
Lesiak, Aleksandra
Ciążyńska, Magdalena
Maciąg, Aldona
Paluchowska, Elwira
Marek-Józefowicz, Luiza
Czajkowski, Rafał
The incidence and management of cutaneous adverse events of the epidermal growth factor receptor inhibitors
title The incidence and management of cutaneous adverse events of the epidermal growth factor receptor inhibitors
title_full The incidence and management of cutaneous adverse events of the epidermal growth factor receptor inhibitors
title_fullStr The incidence and management of cutaneous adverse events of the epidermal growth factor receptor inhibitors
title_full_unstemmed The incidence and management of cutaneous adverse events of the epidermal growth factor receptor inhibitors
title_short The incidence and management of cutaneous adverse events of the epidermal growth factor receptor inhibitors
title_sort incidence and management of cutaneous adverse events of the epidermal growth factor receptor inhibitors
topic Review Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5831275/
https://www.ncbi.nlm.nih.gov/pubmed/29507555
http://dx.doi.org/10.5114/ada.2017.71106
work_keys_str_mv AT owczarekwitold theincidenceandmanagementofcutaneousadverseeventsoftheepidermalgrowthfactorreceptorinhibitors
AT słowinskamonika theincidenceandmanagementofcutaneousadverseeventsoftheepidermalgrowthfactorreceptorinhibitors
AT lesiakaleksandra theincidenceandmanagementofcutaneousadverseeventsoftheepidermalgrowthfactorreceptorinhibitors
AT ciazynskamagdalena theincidenceandmanagementofcutaneousadverseeventsoftheepidermalgrowthfactorreceptorinhibitors
AT maciagaldona theincidenceandmanagementofcutaneousadverseeventsoftheepidermalgrowthfactorreceptorinhibitors
AT paluchowskaelwira theincidenceandmanagementofcutaneousadverseeventsoftheepidermalgrowthfactorreceptorinhibitors
AT marekjozefowiczluiza theincidenceandmanagementofcutaneousadverseeventsoftheepidermalgrowthfactorreceptorinhibitors
AT czajkowskirafał theincidenceandmanagementofcutaneousadverseeventsoftheepidermalgrowthfactorreceptorinhibitors
AT owczarekwitold incidenceandmanagementofcutaneousadverseeventsoftheepidermalgrowthfactorreceptorinhibitors
AT słowinskamonika incidenceandmanagementofcutaneousadverseeventsoftheepidermalgrowthfactorreceptorinhibitors
AT lesiakaleksandra incidenceandmanagementofcutaneousadverseeventsoftheepidermalgrowthfactorreceptorinhibitors
AT ciazynskamagdalena incidenceandmanagementofcutaneousadverseeventsoftheepidermalgrowthfactorreceptorinhibitors
AT maciagaldona incidenceandmanagementofcutaneousadverseeventsoftheepidermalgrowthfactorreceptorinhibitors
AT paluchowskaelwira incidenceandmanagementofcutaneousadverseeventsoftheepidermalgrowthfactorreceptorinhibitors
AT marekjozefowiczluiza incidenceandmanagementofcutaneousadverseeventsoftheepidermalgrowthfactorreceptorinhibitors
AT czajkowskirafał incidenceandmanagementofcutaneousadverseeventsoftheepidermalgrowthfactorreceptorinhibitors